Weekly Topotecan for Recurrent Small Cell Lung Cancer - a Retrospective Anatolian Medical Oncology Group Study

Abstract

.5-40 months). In terms of survival, there was no difference between males and females (p=0.1171).In 17 (27%) patients who were refractory to topotecan or in whom progression occurred other chemotherapies were used. Conclusion: Small cell lung cancer is chemosensitive, but recurrences occur in short time. Other chemotherapy regimens are used in progression. Topotecan is one of them. Patients who were young and in whom recurrences occur late had given better response to topotecan. Because of the retrospective nature of the study, we couldn't reach the records exactly and consequently, rate and duration of response couldn't be calculated. In recurrent SCLC topotecan is one of the treatment choices. But both hematological and non hematological side effects should be taken into consideration.

Asiatic Acid Promotes p21WAF1/CIP1Protein Stability through Attenuation of NDR1/2 Dependent Phosphorylation of p21WAF1/CIP1in HepG2 Human Hepatoma Cells

“…Plant-derived compounds are important source of these nature derived anti-tumor agents. Nearly 3000 plant species have been reported for the treatment of cancer (Altinbas et al, 2012;Boreddy et al, 2013).…”